Methacrylic Copolymer Coating for Intestinal Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug forms with copolymers based on (meth)acrylate monomers face challenges in mechanical stability under high mechanical loads and pH sensitivity, particularly in releasing active ingredients in the upper regions of the intestine, and have limitations in thin coating thickness due to poor resistance and rapid dissolution.
Innovation Solution
A copolymer composed of 20-34% methacrylic acid, 20-69% methyl acrylate, and 0-40% ethyl acrylate, with a glass transition temperature not exceeding 60°C, is used to create drug forms that are mechanically stable and release active ingredients effectively at pH 5.8-6.0, suitable for multiparticulate drug forms and intestinal delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If copolymers based on (meth)acrylate monomers are used to create flexible films with suitable release profiles, then the release characteristics are improved for high pH values, but the mechanical resistance to high mechanical loads deteriorates
Solution Approach 1:
The patent modifies the chemical composition parameters of the copolymer by incorporating carboxylic acid groups with specific pKa values (5.8-6.5) and controlling the ratio of hydrophobic to hydrophilic monomers. This parameter optimization enables the coating to maintain mechanical integrity while achieving controlled release at the target pH range of 5.8-6.0 in the intestine.
Solution Approach 2:
The invention creates a composite copolymer system combining multiple monomer types (acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, and other carboxylic acid-containing monomers) to achieve synergistic effects. The composite structure provides both mechanical strength from the polymer backbone and controlled release properties from the carboxylic acid groups, resolving the contradiction between durability and release performance.
2Loss of substance
If coating thickness is reduced to minimize additives, then the fraction of additives is reduced, but the mechanical stability and resistance to mechanical damage deteriorate
Solution Approach 1:
The patent optimizes the polymer composition parameters to achieve maximum coating efficiency. By controlling the glass transition temperature (Tg) within 0-60°C and optimizing the monomer ratio, the coating achieves adequate mechanical protection at reduced thickness, minimizing the need for additional plasticizers and stabilizers while maintaining durability.
Solution Approach 2:
The copolymer formulation is designed to be self-sufficient, where the polymer matrix itself provides the necessary mechanical strength and protection without requiring disproportionate amounts of additives. The carboxylic acid groups in the copolymer provide both structural integrity and pH-responsive release functionality, eliminating the need for separate release agents or stabilizers.
3Reliability
If copolymers dissolve only above pH 6.5, then the dissolution threshold is raised, but the suitability for active ingredient absorption in upper intestine regions deteriorates
Solution Approach 1:
The patent precisely adjusts the pKa parameters of the carboxylic acid groups in the copolymer to fall within 5.8-6.5, which corresponds to the pH conditions in the upper intestine where active ingredient absorption occurs. This parameter tuning ensures the coating dissolves at the optimal location for drug absorption, improving both dissolution control and physiological adaptability.
Solution Approach 2:
The copolymer exhibits dynamic pH-responsive behavior, transitioning from an intact protective coating at lower pH (stomach) to a dissolved state at the target pH range (upper intestine). This dynamic response allows the coating to adapt to changing physiological conditions, providing protection during gastric transit and enabling release at the optimal absorption site.
4Manufacturing precision
If copolymer films are made thin for specific release characteristics, then the release specificity is improved, but the resistance to mechanical damage during production and storage deteriorates
Solution Approach 1:
The patent optimizes the glass transition temperature (Tg) parameter of the copolymer to be within 0-60°C, which affects the film's flexibility and mechanical properties. By controlling Tg along with monomer composition, the thin coating achieves both the desired release specificity and adequate mechanical resistance to withstand production and storage conditions without damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The copolymer provides enhanced mechanical stability and controlled release of active ingredients in the desired pH range, ensuring effective intestinal delivery and stability during production and storage.
Implementation Method 1
with the proviso that the glass transition temperature of the copolymer in accordance with ISO 11357-2, section 3.3.3, is not more than 60° C.
Implementation Method 2
provide drug forms soluble in intestinal juice which do not release the active ingredient until a pH of about 5.8 to about 6.0
Data Source
AI summary
The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 wt. % methacrylic acid, 20 to 69 wt. % methylacrylate and 0 to 40 wt. % ethylacrylate and, optionally, of 0 to 10 wt. % of additional vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60° C. according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof.